Foxy 5

Drug Profile

Foxy 5

Alternative Names: Foxy-5

Latest Information Update: 17 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator WntResearch
  • Class Antineoplastics; Peptide fragments; Wnt proteins
  • Mechanism of Action Cell movement inhibitors; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 21 Mar 2017 WntResearch plans a phase II trial for Cancer in late 2017
  • 15 Dec 2016 Biomarkers information updated
  • 30 Jan 2016 WntResearch AB plans a phase Ib trial for Breast cancer, Colorectal cancer and Prostate cancer (Metastatic disease) in Denmark and the United Kingdom (IV) (NCT02655952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top